www.fdanews.com/articles/145691-thrombogenics-resubmits-bla-for-ocriplasmin-with-the-fda
ThromboGenics Resubmits BLA for Ocriplasmin With the FDA
April 17, 2012
ThromboGenics announced that it has resubmitted a biologics license application with the FDA for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion including macular hole.
MarketWatch
MarketWatch